These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

600 related articles for article (PubMed ID: 22934764)

  • 41. From fragment screening to potent binders: strategies for fragment-to-lead evolution.
    Eitner K; Koch U
    Mini Rev Med Chem; 2009 Jul; 9(8):956-61. PubMed ID: 19601891
    [TBL] [Abstract][Full Text] [Related]  

  • 42.
    de Souza Neto LR; Moreira-Filho JT; Neves BJ; Maidana RLBR; Guimarães ACR; Furnham N; Andrade CH; Silva FP
    Front Chem; 2020; 8():93. PubMed ID: 32133344
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Successful vemurafenib salvage treatment in a patient with primary refractory hairy cell leukemia and pulmonary aspergillosis.
    Maurer H; Haas P; Wengenmayer T; Lübbert M; Duyster J; Zeiser R
    Ann Hematol; 2014 Aug; 93(8):1439-40. PubMed ID: 24337488
    [No Abstract]   [Full Text] [Related]  

  • 44. Recent progress in fragment-based lead discovery.
    Schulz MN; Hubbard RE
    Curr Opin Pharmacol; 2009 Oct; 9(5):615-21. PubMed ID: 19477685
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Establish an automated flow injection ESI-MS method for the screening of fragment based libraries: Application to Hsp90.
    Riccardi Sirtori F; Caronni D; Colombo M; Dalvit C; Paolucci M; Regazzoni L; Visco C; Fogliatto G
    Eur J Pharm Sci; 2015 Aug; 76():83-94. PubMed ID: 25952103
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Fragment-based approaches in drug discovery and chemical biology.
    Scott DE; Coyne AG; Hudson SA; Abell C
    Biochemistry; 2012 Jun; 51(25):4990-5003. PubMed ID: 22697260
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Progress in the fragment-based drug discovery].
    Ren J; Li J; Shi F; Wang X; He JH; Xu YC; Zhang NX; Xiong B; Shen JK
    Yao Xue Xue Bao; 2013 Jan; 48(1):14-24. PubMed ID: 23600136
    [TBL] [Abstract][Full Text] [Related]  

  • 48. An Automated Microscale Thermophoresis Screening Approach for Fragment-Based Lead Discovery.
    Linke P; Amaning K; Maschberger M; Vallee F; Steier V; Baaske P; Duhr S; Breitsprecher D; Rak A
    J Biomol Screen; 2016 Apr; 21(4):414-21. PubMed ID: 26637553
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Identification and Characterization of Small-Molecule Inhibitors to Selectively Target the DFG-in over the DFG-out Conformation of the B-Raf Kinase V600E Mutant in Colorectal Cancer.
    Yao H; Sun Q; Zhu J
    Arch Pharm (Weinheim); 2016 Oct; 349(10):808-815. PubMed ID: 27624806
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Chemistry-driven Hit-to-lead Optimization Guided by Structure-based Approaches.
    Hoffer L; Muller C; Roche P; Morelli X
    Mol Inform; 2018 Sep; 37(9-10):e1800059. PubMed ID: 30051601
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Fragment screening using surface plasmon resonance optical biosensor technology].
    Miura T
    Yakugaku Zasshi; 2010 Mar; 130(3):341-8. PubMed ID: 20190519
    [TBL] [Abstract][Full Text] [Related]  

  • 52. High-throughput fragment screening by affinity LC-MS.
    Duong-Thi MD; Bergström M; Fex T; Isaksson R; Ohlson S
    J Biomol Screen; 2013 Feb; 18(2):160-71. PubMed ID: 22983162
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Structure-guided fragment-based drug discovery at the synchrotron: screening binding sites and correlations with hotspot mapping.
    Thomas SE; Collins P; James RH; Mendes V; Charoensutthivarakul S; Radoux C; Abell C; Coyne AG; Floto RA; von Delft F; Blundell TL
    Philos Trans A Math Phys Eng Sci; 2019 Jun; 377(2147):20180422. PubMed ID: 31030650
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Mass spectrometry for fragment screening.
    Chan DS; Whitehouse AJ; Coyne AG; Abell C
    Essays Biochem; 2017 Nov; 61(5):465-473. PubMed ID: 28986384
    [TBL] [Abstract][Full Text] [Related]  

  • 55. NMR screening and hit validation in fragment based drug discovery.
    Campos-Olivas R
    Curr Top Med Chem; 2011; 11(1):43-67. PubMed ID: 20809889
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The discovery of vemurafenib for the treatment of BRAF-mutated metastatic melanoma.
    Kim A; Cohen MS
    Expert Opin Drug Discov; 2016 Sep; 11(9):907-16. PubMed ID: 27327499
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Using fragment-based technologies to target protein-protein interactions.
    Bower JF; Pannifer A
    Curr Pharm Des; 2012; 18(30):4685-96. PubMed ID: 22650253
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A comparative study of fragment screening methods on the p38α kinase: new methods, new insights.
    Pollack SJ; Beyer KS; Lock C; Müller I; Sheppard D; Lipkin M; Hardick D; Blurton P; Leonard PM; Hubbard PA; Todd D; Richardson CM; Ahrens T; Baader M; Hafenbradl DO; Hilyard K; Bürli RW
    J Comput Aided Mol Des; 2011 Jul; 25(7):677-87. PubMed ID: 21732248
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Biophysical screening for the discovery of small-molecule ligands.
    Ciulli A
    Methods Mol Biol; 2013; 1008():357-88. PubMed ID: 23729259
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Fragment-Based Phenotypic Lead Discovery: Cell-Based Assay to Target Leishmaniasis.
    Ayotte Y; Bilodeau F; Descoteaux A; LaPlante SR
    ChemMedChem; 2018 Jul; 13(14):1377-1386. PubMed ID: 29722149
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.